18.09.2017 |
Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
Related items
10.09.2024
Leiden, The Netherlands, 10 september 2024 VarmX, a biotech company focusing on the development of innovative approaches for the appointed experienced…
25.05.2023
Leiden, The Netherlands, 25 May 2023 VarmX, a biotech company focusing on the development of innovative approaches for the reversal…